Shanghai Medicilon Inc.

  On July 17 th , Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma") reached a strategic collaboration agreement.  The cooperative efforts will focus on preclinical evaluation of new drug modalities, particularly  ADCs ,  small nucleic acids , and  CGT (cell and gene therapy) drugs . The goal of this partnership is to advance the innovation of the Chinese pharmaceutical industry to compete on an international level. The elevated commitment to collaboration between Medicilon and Hengrui Pharma builds upon the solid foundation from years of experience and well-established trust.  The organizations plan to integrate Medicilon's preclinical R&D expertise with Hengrui Pharma's innovative strategies and market influence. Medicilon will leverage its technological advantages in drug discovery and development to provide Hengrui Pharma with a range of preclinical services, focusing on efficacy testing, pharmacok...

  Fungal infections have become an urgent challenge in the global healthcare field, posing a particularly severe threat to immunocompromised patient groups, including those with cancer, organ transplants, and HIV.  However, the progress of innovative drug development for antifungal infections in China has been relatively slow. Coupled with the limitations on the use of antifungal drugs and the increasing resistance of fungi, there is an urgent need to explore and develop new treatment strategies to address this global medical challenge. Against this development background, Sungening Biological (Sungening) has successfully obtained an implicit permission from the National Medical Products Administration for clinical trials (acceptance number: CXHL2400203) for its first innovative drug, SG1001. Additionally, Sungening has signed an agreement with Livzon Pharmaceutical Group, regarding the rights to SG1001 in the Greater China region.  This not only highlights the potential ...

On May 9th, the "2024 Top 100 Future Healthcare" series rankings were officially unveiled. Medicilon successfully made it onto the list and was awarded the "Best Client Satisfaction Pharmaceutical CRO" due to its outstanding market performance, human resources, knowledge resources, and essential partnership resources. The "2024 Top 100 Future Healthcare" list was jointly launched by vbdata.cn, VB100, and VCBeat Research, aiming to select truly representative Chinese innovative medical practitioners who embody the future of healthcare and drive the innovative transformation process in the health and medical industry. This selection process, with a strict and fair evaluation mechanism, combines multiple stages including independent company applications, professional evaluations, cross-evaluations by supporting organizations, and final review by an expert committee. It focuses on the growth and annual performance of candidate companies across 17 secondary in...

  Recently, the Shanghai Science and Technology Commission officially issued the "Notice on the Announcement of the List of 2023 Shanghai Science and Technology Little Giants (Including Cultivation) Enterprises".   Medicilon Preclinical Research (Shanghai) LLC (MPR), a subsidiary of Medicilon , was recognized as one of the 2023 Shanghai Science and Technology Little Giants Company.  This is the second time Medicilon has received this honorary title. About Shanghai Science and Technology Little Giant The Shanghai Science and Technology Little Giant Project is jointly promoted by the Shanghai Science and Technology Commission, the Municipal Economic and Information Technology Commission, and the Municipal Finance Bureau.  It aims to deeply implement the innovation-driven development strategy, accelerate the construction of a technological innovation center with global influence, and create a large number of small technological giant enterprises with competitive advanta...

  Recently, Shanghai Medicilon Inc. (Medicilon) won the "Best Partner Award" from SicaGene.  The strong support provided in collaboration projects has been recognized by client again. Medicilon and SicaGene: Go Deep Alone, Go Far Together The collaboration stems from a shared vision in the field of nucleic acid drugs.  Antisense oligonucleotide drugs can break through the "undruggable targets" limitations of traditional small molecule drugs, but they also have extremely high technical barriers and development difficulties.  As one of the first China innovative pharmaceutical companies to enter the ASO field, SicaGene has independently developed and constructed core technology platforms such as  SicaScreenTM、SicaChemistryTM、SicaDeliveryTM , focusing on drug development in the fields of cardiovascular disease, viruses, and ophthalmology.  SicaGene has also achieved efficient development of ASO drugs with high activity, low dosage, long administration cycle, g...

On January 8, 2024, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (Changshan Pharmaceutical) issued an announcement, saying that its holding subsidiary Changshan Kaijiejian Biopharmaceutical Research and Development (Hebei) Co., Ltd. has recently received the approval of the National Medical Products Administration (NMPA) to issue a "Drug Clinical Trial Approval Notice" for the new Class 1 chemical drug CSCJC3456 tablets. Shanghai Medicilon Inc. (Medicilon), as a partner of Changshan Pharmaceutical, has efficiently completed most of the preclinical research work of CSCJC3456, including drug efficacy, pharmacokinetics and safety evaluation promoting the project to quickly complete the preclinical research and development process. Accelerate Drug Innovation and Development      Medicilon’s One-Stop Shop to Assist Drug Preclinical Research and Development As a one-stop preclinical R&D service platform, Medicilon actively expands its development layout in popular a...

  On January 8, Dr. Xiaobao Yang, Chairman and CEO of Gluetacs Therapeutics (Gluetacs) awarded Shanghai Medicilon Inc. (Medicilon) the "2023 Best Partner Award”.  Dr. Jinna Cai, Chief Commercial Officer of Medicilon, and Bolin Zhang, Director of CMC of Key Account Development Department, attended the award ceremony. Medicilon and Gluetacs: Going in both directions, achieving each other’s achievements Dr. Xiaobao Yang, Chairman and CEO of Gluetacs, affirmed the efficient service capabilities of Medicilon’s one-stop biopharmaceutical preclinical R&D service platform at the award ceremony, “In the past two years, Gluetacs’  GT919  and GT929 have been clinically approved in China and the United States, which is inseparable from Medicilon’s strong support.  Even for difficult trials, the Medicilon team was able to deliver beyond expectations, which makes us feel reassured and confident in our future collaboration.” Dr. Jinna Cai, Chief Commercial Officer of Medic...

In the 2023, how to better empower the research and development of new drugs? How to better meet the R&D needs of global clients? How to organize resources and build an ecosystem... This is a heavy "examination paper" thrown to Medicilon by the times. As an enabler of the pharmaceutical industry, Medicilon adheres to its original mission, works hard and moves forward resolutely, writing Medicilon's "answer"for 2023! 1 Answer the “Basic Questions” of New Drug Empowerment  Consolidate “One-Stop” R&D Services Focusing on the integrated strategy of preclinical research, Medicilon continued to deepen the integrated development, extended the advantages of integration from chemical drugs to the field of biological drugs, and further complement the capabilities of drug discovery and pharmaceutical research capabilities of biological drugs. By introducing advanced equipment investment and a team of senior talents, Medicilon has improved its one-stop preclinical R...

  On December 22, 2023, Medicilon and North America 100 Angel Investment LLC announced that the two parties had officially signed a strategic collaboration agreement in Boston.  In the future, the two parties will conduct diversified and in-depth cooperation in industrial investment, customer development, mergers and acquisitions, and industrial implementation support.  This collaboration will bring huge opportunities to both parties and promote the global development of both parties in the field of innovative drug research and development. About North America 100 Angel Investment LLC North America 100 Angel Investment LLC is registered in Massachusetts, USA.  The company focuses on the field of life sciences, including but not limited to medicine, equipment, medical services and other fields to promote the development of the life sciences industry through industrial investment, industry cultivation, project promotion, exhibition organization, consulting services an...

  On December 5, the awarding ceremony for the first batch of Shanghai innovative enterprise headquarters was held.  Zheng Gong, Deputy Secretary of the Shanghai Municipal Party Committee and Mayor, awarded plaques to 40 innovative enterprise headquarters and took a group photo.   Shanghai Medicilon Inc. (Medicilon) has become one of the first 10 biopharmaceutical companies selected as Shanghai's innovative enterprise headquarters.  This is the first time that Shanghai has independently recognized the headquarters of innovative enterprises, providing support to accelerate the development of Shanghai's innovative economy and build a technological innovation center with global influence.  This honor signifies that Medicilon's performance in technological innovation in new drug research and development has been highly recognized by the Shanghai Municipal Government. The 40 innovative enterprise headquarters awarded licenses this time cover key industrial fields su...